What is the significance of a protein‑creatinine ratio of 879 mg/g and how should it be managed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

A Protein-Creatinine Ratio of 879 mg/g Represents Severe Proteinuria Requiring Urgent Evaluation and Management

A protein-creatinine ratio (PCR) of 879 mg/g indicates massive proteinuria that demands immediate clinical assessment to determine the underlying cause and initiate appropriate treatment, as this level is associated with significant risk for kidney disease progression and adverse outcomes.

Clinical Significance

Your PCR of 879 mg/g is approximately 3 times the threshold for nephrotic-range proteinuria and falls into the category of massive proteinuria. To put this in context:

  • Normal: <200 mg/g 1, 2
  • Abnormal/significant: ≥300 mg/g (0.3 mg/mg) 3
  • Nephrotic-range: >3,500 mg/g 1
  • Your level: 879 mg/g - severe proteinuria

This level correlates with approximately 0.9-1.0 grams of protein loss per day in a 24-hour period 4, 5, which is clinically significant and requires investigation.

Context-Specific Interpretation

If You Are Pregnant:

This is a medical emergency. A PCR >900 mg/mmol (approximately 800 mg/g) is associated with worse maternal outcomes 3. In pregnancy:

  • PCR ≥30 mg/mmol (0.3 mg/mg) is abnormal 3
  • Massive proteinuria (>5 g/24h) associates with more severe neonatal outcomes 3
  • Your level suggests preeclampsia with severe features requiring immediate obstetric evaluation
  • Blood pressure must be checked within 15 minutes if ≥160/110 mmHg 3

If You Have Lupus or Autoimmune Disease:

This level indicates active lupus nephritis requiring immunosuppressive therapy 6, 7:

  • Kidney biopsy is indicated when proteinuria ≥500 mg/g 6
  • Treatment goals include reducing proteinuria to <500-700 mg/g by 12 months 6
  • Immediate initiation of mycophenolate mofetil (2-3 g/day) or cyclophosphamide plus glucocorticoids is recommended 6, 7

If You Have Chronic Kidney Disease:

A PCR of 879 mg/g indicates high risk for CKD progression 8:

  • Levels >700-1,000 mg/g carry 4.6 times higher risk of progression compared to <300 mg/g 8
  • This level requires aggressive antiproteinuric therapy
  • ACE inhibitors or ARBs are mandatory unless contraindicated 7

Immediate Management Steps

1. Confirm the Result

  • Repeat the test on a first morning void urine sample to confirm persistence 1
  • Avoid vigorous exercise 24 hours before collection 1
  • If confirmed on 2 of 3 samples, proteinuria is persistent and requires full evaluation 1

2. Determine the Cause

Evaluate for:

  • Pregnancy status (if applicable) - check blood pressure immediately
  • Diabetes mellitus - check HbA1c, blood glucose
  • Autoimmune disease - ANA, anti-dsDNA, complement levels (C3, C4)
  • Kidney function - serum creatinine, eGFR
  • Nephrotic syndrome features - serum albumin, cholesterol, edema
  • Hematuria - urine microscopy for red blood cells, casts

3. Initiate Protective Therapy

While awaiting definitive diagnosis:

  • Start ACE inhibitor or ARB if not pregnant and no contraindications 7
  • Target blood pressure ≤130/80 mmHg 7
  • Consider statin therapy if LDL >100 mg/dL 7
  • Assess thrombosis risk - if nephrotic syndrome confirmed (albumin <3 g/dL), thromboprophylaxis may be needed 3

4. Specialist Referral

Nephrology consultation is mandatory at this level of proteinuria:

  • Kidney biopsy may be indicated to determine specific diagnosis 6, 7
  • Specialized treatment protocols depend on underlying cause
  • Close monitoring required (every 3-6 months initially) 6

Treatment Goals

Your target should be to reduce proteinuria to:

  • <500-700 mg/g by 12 months (complete clinical response) 6
  • 50% reduction by 6 months (partial response) 6
  • 25% reduction by 3 months (early response) 6

Failure to show improvement by these timepoints warrants treatment intensification or change in therapy 6.

Critical Pitfalls to Avoid

  • Do not dismiss this as "mild" proteinuria - 879 mg/g is severe
  • Do not delay evaluation in pregnancy - this could represent life-threatening preeclampsia
  • Do not rely on dipstick alone - quantitative PCR is essential for monitoring 3
  • Do not use 24-hour urine collections - spot PCR is equally accurate and more practical 1, 4
  • Do not ignore even if asymptomatic - proteinuria at this level predicts poor outcomes regardless of symptoms

Monitoring Strategy

Once treatment initiated:

  • Repeat PCR monthly for first 3-6 months 6
  • Check serum creatinine/eGFR with each PCR measurement
  • Monitor for medication side effects (hyperkalemia with ACE-I/ARB, infection risk with immunosuppression)
  • Annual screening thereafter if proteinuria controlled 1

References

Research

Comparison of 24-hour urinary protein and protein-to-creatinine ratio in the assessment of proteinuria.

Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2009

Research

Protein-to-creatinine ratio in spot urine samples as a predictor of quantitation of proteinuria.

Clinica chimica acta; international journal of clinical chemistry, 2004

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.